Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Inclusion Criteria:

• Diagnosis of Non-Squamous Non-Small Cell Lung Cancer

• Receipt of at least one but not more than two prior treatment regimens in theadvanced setting

• Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-basedchemotherapy in combination or in sequence (i.e., platinum-based chemotheraphyfollowed by checkpoint inhibitor therapy)

• Most recent treatment regimen must have included a checkpoint inhibitor therapy withradiographic disease progression on or after treatment

• Candidate to receive docetaxel as second or third line therapy

Exclusion Criteria:

• Uncontrolled brain metastases

• Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions

• Unacceptable toxicity with prior checkpoint inhibitor therapy

• Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, otherthan maintenance chemotherapy

• Impaired heart function